Literature DB >> 28423377

Risk and Survival of Patients with Head and Neck Cutaneous Melanoma: National Perspective.

Zaid Al-Qurayshi1, Mohamed Hassan, Sudesh Srivastav, Steven Sperry, Nitin Pagedar, John Hamner, Emad Kandil.   

Abstract

OBJECTIVE: Head and neck cutaneous melanoma represents a distinct entity of skin cancer. We aim to examine management and survival of patients with head and neck cutaneous melanoma.
METHODS: A retrospective cohort study utilizing the National Cancer Database, 2004-2012.
RESULTS: A total of 20,322 (21.2%) head and neck melanomas and 75,547 (78.8%) melanomas of other sites were included. The median follow-up time of head and neck melanoma was 41.6 months (interquartile range: 22.9-68.2 months). Patients with melanoma of the head and neck were more likely to be ≥65 years old, male, and/or white (p < 0.001 each). Positive surgical margin was more prevalent in head and neck melanoma [OR: 2.19, 95% CI: (2.03, 2.37)], and was associated with a lower survival [HR: 1.41, 95% CI: (1.28, 1.57)]. High positive lymph node ratio was associated with a lower survival [HR: 2.00, 95% CI: (1.13, 3.57)]. Adjuvant immunotherapy was associated with an improved survival [HR: 0.67, 95% CI: (0.57, 0.80)].
CONCLUSION: Head and neck cutaneous melanoma is associated with certain demographics. Surgical margin status, lymph node ratio, and immunotherapy are independently associated with overall survival.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Cutaneous melanoma; Disparities; Immunotherapy; Lymph node biopsy; Surgical margin

Mesh:

Year:  2017        PMID: 28423377     DOI: 10.1159/000458530

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  6 in total

1.  Do Oncologic Outcomes From Head and Neck Versus Truncal and Extremity Melanoma Differ? A Single-Institution Single-Subspecialty Experience.

Authors:  Kirsten M Baecher; Michael K Turgeon; Caroline R Medin; Geetha Mahendran; Terrill M Flakes; Keith A Delman; Michael C Lowe
Journal:  Am Surg       Date:  2021-11-11       Impact factor: 0.688

2.  Head & neck melanoma: A 22-year experience of recurrence following sentinel lymph node biopsy.

Authors:  Kristen A Echanique; Shabnam Ghazizadeh; Andy Moon; Kera Kwan; Peter A Pellionisz; Dennis Rünger; David Elashoff; Maie St John
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-06-21

3.  Head and neck cutaneous melanoma: 5-year survival analysis in a Serbian university center.

Authors:  Aleksandar Višnjić; Predrag Kovačević; Asen Veličkov; Mariola Stojanović; Stefan Mladenović
Journal:  World J Surg Oncol       Date:  2020-11-29       Impact factor: 2.754

4.  Head and neck melanoma: outcome and predictors in a population-based cohort study.

Authors:  Steffen Spoerl; Gerrit Spanier; Elena Reiter; Michael Gerken; Sebastian Haferkamp; Jirka Grosse; Konstantin Drexler; Tobias Ettl; Monika Klinkhammer-Schalke; René Fischer; Silvia Spoerl; Torsten E Reichert; Christoph Klingelhöffer
Journal:  Head Face Med       Date:  2021-10-22       Impact factor: 2.246

5.  Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.

Authors:  Charlotte Andrieu; Niamh McNamee; Anne-Marie Larkin; Alanna Maguire; Roopika Menon; Judith Mueller-Eisert; Noel Horgan; Susan Kennedy; Giuseppe Gullo; John Crown; Naomi Walsh
Journal:  Med Sci (Basel)       Date:  2022-05-24

6.  Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients.

Authors:  Nir Hirshoren; Roni Yoeli; Jonathan E Cohen; Jeffrey M Weinberger; Nadia Kaplan; Sharon Merims; Tamar Peretz; Michal Lotem
Journal:  PLoS One       Date:  2020-04-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.